Last reviewed 2026-04-23 · How we verify

Perfusion of treatment Rituximab

Perfusion of treatment Rituximab is a Monoclonal antibody (anti-CD20) Small molecule drug developed by Rennes University Hospital. It is currently in Phase 3 development for Rheumatoid arthritis (moderate to severe), Granulomatosis with polyangiitis (GPA), Microscopic polyangiitis (MPA).

Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.

Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Used for Rheumatoid arthritis (moderate to severe), Granulomatosis with polyangiitis (GPA), Microscopic polyangiitis (MPA).

At a glance

Mechanism of action

Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes. By binding to CD20, it triggers immune-mediated destruction of B cells through multiple mechanisms including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. This B cell depletion reduces autoimmune and inflammatory responses in conditions driven by pathogenic B cells.

Approved indications

• Rheumatoid arthritis (moderate to severe)
• Granulomatosis with polyangiitis (GPA)
• Microscopic polyangiitis (MPA)
• B-cell non-Hodgkin's lymphoma
• Chronic lymphocytic leukemia

Common side effects

• Infusion reactions
• Infections (including serious infections)
• Cytopenias (anemia, thrombocytopenia, neutropenia)
• Fatigue
• Fever
• Nausea

Key clinical trials

• RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. (PHASE3)
• Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis (PHASE4)
• Rituximab in Patients With Acute Rheumatic Fever (PHASE2)
• Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia (NA)
• Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions (PHASE3)
• Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid (PHASE3)
• Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma (PHASE2)
• Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Perfusion of treatment Rituximab CI brief — competitive landscape report
• Perfusion of treatment Rituximab updates RSS · CI watch RSS
• Rennes University Hospital portfolio CI

Frequently asked questions about Perfusion of treatment Rituximab

Related

• Drug class: All Monoclonal antibody (anti-CD20) drugs
• Target: All drugs targeting CD20
• Manufacturer: Rennes University Hospital — full pipeline
• Therapeutic area: All drugs in Immunology
• Indication: Drugs for Rheumatoid arthritis (moderate to severe)
• Indication: Drugs for Granulomatosis with polyangiitis (GPA)
• Indication: Drugs for Microscopic polyangiitis (MPA)
• Compare: Perfusion of treatment Rituximab vs similar drugs
• Pricing: Perfusion of treatment Rituximab cost, discount & access